Comparison | Proteins | Best point | AUC | Minimum specificity of 0.95 (screening) | Minimum sensitivity of 0.95 (diagnostic) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sensitivity | Specificity | Sensitivity | Specificity | Sensitivity | Specificity | |||||||||
Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |||
Analysis discovery | ||||||||||||||
Benign tumors versus ovarian cancer stage I–II | All | 0.68 | 0.07 | 0.73 | 0.08 | 0.72 | 0.33 | 0.11 | 0.96 | 0.01 | 0.96 | 0.01 | 0.07 | 0.08 |
Benign tumors versus ovarian cancer stage III–IV | All | 0.93 | 0.04 | 0.93 | 0.03 | 0.95 | 0.86 | 0.07 | 0.96 | 0.01 | 0.96 | 0.00 | 0.54 | 0.25 |
Benign tumors versus ovarian cancer stage I–IV | All | 0.79 | 0.04 | 0.85 | 0.04 | 0.86 | 0.61 | 0.07 | 0.96 | 0.01 | 0.96 | 0.01 | 0.18 | 0.10 |
Population ontrols versus ovarian cancer stage I–II | All | 0.70 | 0.07 | 0.75 | 0.07 | 0.74 | 0.43 | 0.07 | 0.96 | 0.01 | 0.97 | 0.01 | 0.02 | 0.05 |
Population controls versus ovarian cancer stage III–IV | All | 0.94 | 0.03 | 0.96 | 0.03 | 0.97 | 0.92 | 0.05 | 0.96 | 0.01 | 0.97 | 0.01 | 0.47 | 0.29 |
Population controls versus ovarian stage I–IV | All | 0.75 | 0.05 | 0.87 | 0.05 | 0.86 | 0.66 | 0.06 | 0.95 | 0.00 | 0.96 | 0.01 | 0.13 | 0.10 |
Benign tumors versus endometrial cancer | All | 0.77 | 0.05 | 0.79 | 0.05 | 0.83 | 0.45 | 0.11 | 0.96 | 0.01 | 0.97 | 0.01 | 0.09 | 0.11 |
Population controls versus endometrial cancer | All | 0.69 | 0.06 | 0.78 | 0.06 | 0.76 | 0.43 | 0.07 | 0.95 | 0.00 | 0.97 | 0.01 | 0.07 | 0.07 |
Ovarian cancer versus endometrial cancer | All | 0.84 | 0.04 | 0.88 | 0.04 | 0.89 | 0.64 | 0.17 | 0.97 | 0.01 | 0.96 | 0.01 | 0.42 | 0.16 |
Replication | ||||||||||||||
Benign tumors versus ovarian cancer stage I–II | All | 0.73 | 0.08 | 0.74 | 0.07 | 0.76 | 0.29 | 0.11 | 0.97 | 0.01 | 0.97 | 0.01 | 0.19 | 0.14 |
Benign tumors versus ovarian cancer stage III–IV | All | 0.88 | 0.03 | 0.92 | 0.03 | 0.92 | 0.81 | 0.07 | 0.96 | 0.01 | 0.96 | 0.01 | 0.58 | 0.15 |
Benign tumors versus ovarian cancer stage I–IV | All | 0.83 | 0.04 | 0.87 | 0.04 | 0.89 | 0.68 | 0.10 | 0.97 | 0.01 | 0.96 | 0.01 | 0.48 | 0.12 |
Population ontrols versus ovarian cancer stage I–II | All | 0.62 | 0.09 | 0.68 | 0.11 | 0.63 | 0.24 | 0.12 | 0.97 | 0.01 | 0.97 | 0.01 | 0.06 | 0.10 |
Population controls versus ovarian cancer stage III–IV | All | 0.85 | 0.03 | 0.92 | 0.04 | 0.89 | 0.78 | 0.09 | 0.97 | 0.01 | 0.96 | 0.01 | 0.35 | 0.15 |
Population controls versus ovarian stage I–IV | All | 0.77 | 0.05 | 0.85 | 0.05 | 0.86 | 0.62 | 0.10 | 0.96 | 0.01 | 0.96 | 0.01 | 0.21 | 0.11 |
Benign tumors versus endometrial cancer | All | 0.70 | 0.06 | 0.67 | 0.07 | 0.72 | 0.22 | 0.09 | 0.97 | 0.01 | 0.96 | 0.01 | 0.25 | 0.08 |
Population controls versus endometrial cancer | All | 0.64 | 0.07 | 0.72 | 0.08 | 0.71 | 0.24 | 0.14 | 0.97 | 0.01 | 0.96 | 0.01 | 0.10 | 0.06 |
Ovarian cancer versus endometrial cancer | All | 0.73 | 0.03 | 0.77 | 0.04 | 0.78 | 0.36 | 0.06 | 0.96 | 0.00 | 0.96 | 0.00 | 0.11 | 0.06 |
Benign tumors versus ovarian cancer stage I–II | CA125/HE4 | 0.73 | 0.08 | 0.73 | 0.07 | 0.78 | 0.38 | 0.11 | 0.97 | 0.01 | 0.97 | 0.01 | 0.30 | 0.16 |
Benign tumors versus ovarian cancer stage III–IV | CA125/HE4 | 0.87 | 0.03 | 0.87 | 0.04 | 0.90 | 0.74 | 0.06 | 0.97 | 0.02 | 0.96 | 0.01 | 0.37 | 0.12 |
Benign tumors versus ovarian cancer stage I–IV | CA125/HE4 | 0.79 | 0.03 | 0.87 | 0.04 | 0.87 | 0.67 | 0.06 | 0.97 | 0.01 | 0.96 | 0.01 | 0.39 | 0.10 |
Population ontrols versus ovarian cancer stage I–II | CA125/HE4 | 0.59 | 0.08 | 0.77 | 0.10 | 0.66 | 0.35 | 0.11 | 0.97 | 0.01 | 0.97 | 0.01 | 0.14 | 0.07 |
Population controls versus ovarian cancer stage III–IV | CA125/HE4 | 0.84 | 0.03 | 0.89 | 0.04 | 0.86 | 0.74 | 0.07 | 0.97 | 0.01 | 0.96 | 0.00 | 0.17 | 0.09 |
Population controls versus ovarian stage I–IV | CA125/HE4 | 0.77 | 0.03 | 0.88 | 0.05 | 0.81 | 0.65 | 0.08 | 0.96 | 0.00 | 0.96 | 0.01 | 0.14 | 0.07 |